Endoscopic Therapy for Laterally Spreading Tumors (LSTs)
LST
Hybrid Versus Conventional Endoscopic Submucosal Dissection for Laterally Spreading Tumors (LSTs): A Retrospective Multicenter Study
1 other identifier
observational
890
1 country
1
Brief Summary
This study will retrospectively include LST patients who were admitted to 6 medical centers (The Second Affiliated Hospital, College of Medicine, Zhejiang University; The Affiliated Jinhua Hospital, Zhejiang University School of Medicine; First Affiliated Hospital of Huzhou University; The Second Hospital of Jiaxing; Jinhua People's Hospital; Lanxi People's Hospital) from 2020.05.01 to 2023.04.30 with the purpose of comparing the efficacy and safety of hybrid ESD and ESD in the treatment of colorectal LST. The complete resection rate, operation time, operation cost, intraoperative and postoperative complications of hybrid ESD and ESD LST will be compared. To provide strong evidence for the selection of endoscopic treatment strategies for LST.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedFirst Submitted
Initial submission to the registry
June 13, 2024
CompletedFirst Posted
Study publicly available on registry
June 18, 2024
CompletedJune 18, 2024
May 1, 2020
3 years
June 13, 2024
June 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
complete resection rate
One-time complete excision
2 weeks
Study Arms (2)
conventional ESD
Submucosal injection of methylene blue solution at various sites was performed, followed by periphery incision using a dual knife. The submucosal injection was administered multiple times, followed by the utilization of an IT knife for submucosal separation and gradual excision of the lesion. In cases of significant bleeding at the wound site, electrocoagulation hemostatic forceps were employed for hemostasis.
hybrid ESD
The submucosal injection and circumferential incision of the Hybrid ESD were performed as described above. Subsequently, snaring was conducted post submucosal dissection utilizing a polypectomy snare for complete lesion removal. Careful attention was paid during excision to avoid muscle layer penetration and to control cutting speed in order to mitigate the potential for hemorrhage and perforation. The subsequent steps of the procedure closely followed the conventional ESD methodology outlined previously.
Interventions
Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
Eligibility Criteria
This study involved a multicenter retrospective analysis of 890 consecutive patients with a colorectal LST \> 10 millimeters who underwent endoscopic treatment at 6 medical centers (The Second Affiliated Hospital, College of Medicine, Zhejiang University; The Affiliated Jinhua Hospital, Zhejiang University School of Medicine; First Affiliated Hospital of Huzhou University; The Second Hospital of Jiaxing; Jinhua People's Hospital; Lanxi People's Hospital) between May 2020 and April 2023.
You may qualify if:
- Age ≥18 years old;
- LST lesion diameter \>1cm;
- Medical record data integrity
You may not qualify if:
- Pedicle lesions;
- Resection of residual lesions after endoscopic treatment;
- Advanced endoscopic imaging showed submucosal infiltrating lesions.
- The lesions are in patients with inflammatory bowel disease;
- Familial polyposis;
- Electrolyte abnormalities;
- Coagulation dysfunction;
- Pregnant or lactating patients;
- Taking nonsteroidal anti-inflammatory drugs or anticoagulants;
- A history of alcoholism;
- Severe organ failure;
- Medical records are incomplete
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310009, China
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2024
First Posted
June 18, 2024
Study Start
May 1, 2020
Primary Completion
April 30, 2023
Study Completion
December 30, 2023
Last Updated
June 18, 2024
Record last verified: 2020-05